CAS NO: | 161715-24-8 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 497.63 |
---|---|
Formula | C22H31N3O6S2 |
CAS No. | 161715-24-8 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 99 mg/mL (198.9 mM) |
Water: <1 mg/mL | |
Ethanol: 87 mg/mL (174.8 mM) | |
Other info | Chemical Name: (pivaloyloxy)methyl (4R,5R,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate InChi Key: SNUDIPVBUUXCDG-GBOPCIDUSA-N InChi Code: InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3/t11-,12-,14-,15+/m1/s1 SMILES Code: O=C1[C@H]([C@H](O)C)[C@]2([H])[C@@H](C)C(SC3CN(C4=NCCS4)C3)=C(C(OCOC(C(C)(C)C)=O)=O)N12 |
Synonyms | L-084, L 084, L084, ME1211; ME-1211; ME 1211; SPR994; SPR-994; SPR 994; TBM-PI |
In Vitro | In vitro activity: Tebipenem Pivoxil has high intestinal apical membrane permeability due to plural intestinal transport routes, including the uptake transporters such as OATP1A2 and OATP2B1 as well as simple diffusion. Tebipenem Pivoxil is quickly converted to tebipenem (TBPM), an active form of Tebipenem Pivoxil. Tebipenem Pivoxil are absorbed quickly, and the bioavailability is 71.4%, 59.1%, 34.8% and 44.9%, respectively, in mouse, rat, dog and monkey. Tebipenem shows the strongest bactericidal activity as early as 2 h after exposure at two times the MIC. Tebipenem shows higher affinities for PBP 1A and PBP 2B, high-molecular-weight enzymes, and for PBP 3, a low-molecular-weight enzyme, than for PBP 2X. Tebipenem has a potent activity against Neisseria gonorrhoeae; its activity is comparable to it of cefixime that has most potent activity among oral antibiotics. |
---|---|
In Vivo | Tebipenem Pivoxil results in survival rate of 83%, compared with 25% survival for Amoxicillin and 0% survival for controls in animal model of otitis media. Tebipenem exhibits slow tight-binding inhibition at low micromolar concentrations versus the chromogenic substrate nitrocefin. Tebipenem acyl-enzyme complex remains stable for greater than 90 min and exists as mixture of the covalently bound drug and the bound retro-aldol cleavage product. |
Animal model | N/A |
Formulation & Dosage | N/A |
References | [1]. El-Gamal, M.I. and C.H. Oh, Current status of carbapenem antibiotics. Curr Top Med Chem, 2010. 10(18): p. 1882-97. [2]. Fujimoto, K., et al., Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrob Agents Chemother, 2013. 57(2): p. 697-707. [3]. Kato, K., et al., Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm, 2010. 7(5): p. 1747-56. |